PLx Pharma Inc. (NASDAQ: PLXP) stock fell -36.68% on Friday to $1.64 against a previous-day closing price of $2.59. With 2.68 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.18 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $2.0000 whereas the lowest price it dropped to was $1.5000. The 52-week range on PLXP shows that it touched its highest point at $21.19 and its lowest point at $1.81 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 3.84.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PLXP was down-trending over the past week, with a drop of -25.11%, but this was down by -18.00% over a month. Three-month performance dropped to -19.21% while six-month performance fell -74.57%. The stock lost -90.34% in the past year, while it has lost -79.53% so far this year. A look at the trailing 12-month EPS for PLXP yields -1.86 with Next year EPS estimates of -0.94. For the next quarter, that number is -0.44. This implies an EPS growth rate of -17.90% for this year and 46.90% for next year. EPS is expected to grow by 40.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -12.90%.
Float and Shares Shorts:
At present, 27.54 million PLXP shares are outstanding with a float of 23.05 million shares on hand for trading. On Jul 14, 2022, short shares totaled 1.55 million, which was 5.62% higher than short shares on Jun 14, 2022. In addition to Mr. Michael J. Valentino as the firm’s Exec. Chairman, Ms. Natasha Giordano serves as its CEO, Pres & Director.
Through their ownership of 41.44% of PLXP’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.84% of PLXP, in contrast to 6.04% held by mutual funds. Shares owned by individuals account for 33.20%. As the largest shareholder in PLXP with 8.80% of the stake, White Rock Capital Management LP holds 2,422,900 shares worth 2,422,900. A second-largest stockholder of PLXP, MSD Partners LP, holds 1,875,000 shares, controlling over 6.81% of the firm’s shares. Park West Asset Management LLC is the third largest shareholder in PLXP, holding 1,473,218 shares or 5.35% stake. With a 2.65% stake in PLXP, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 728,870 shares are owned by the mutual fund manager. The Nordea 1 – Global Small Cap Fund, which owns about 1.21% of PLXP stock, is the second-largest Mutual Fund holder. It holds 333,944 shares valued at 0.74 million. Vanguard Extended Market Index Fu holds 1.20% of the stake in PLXP, owning 329,367 shares worth 0.73 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PLXP since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PLXP analysts setting a high price target of $21.00 and a low target of $10.00, the average target price over the next 12 months is $14.00. Based on these targets, PLXP could surge 1180.49% to reach the target high and rise by 509.76% to reach the target low. Reaching the average price target will result in a growth of 753.66% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PLXP will report FY 2022 earnings on 03/10/2023. Analysts have provided yearly estimates in a range of -$1.80 being high and -$1.97 being low. For PLXP, this leads to a yearly average estimate of -$1.86. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. PLx Pharma Inc. surprised analysts by $0.04 when it reported -$0.52 EPS against a consensus estimate of -$0.56. The surprise factor in the prior quarter was $0.33. Based on analyst estimates, the high estimate for the next quarter is -$0.42 and the low estimate is -$0.47. The average estimate for the next quarter is thus -$0.44.